Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of
this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01.

Other Events.

On August 23, 2017, ImmunoCellular Therapeutics, Ltd. issued a
press release entitled ImmunoCellular Therapeutics Provides Business Update on Research and Development Programs and Future Strategy, a copy of which is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

Description

99.1

Press Release, dated August 23, 2017.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

Date: August 28, 2017

IMMUNOCELLULAR THERAPEUTICS, LTD.

By:

/s/ David Fractor

David Fractor

Chief Financial Officer

EXHIBIT INDEX

Exhibit

Description

99.1

Press Release, dated August 23, 2017.

Exhibit 99.1

ImmunoCellular Therapeutics Provides Business Update on Research and Development

Programs and Future Strategy

- Near-Term Milestones Anticipated in
Stem-to-T-Cell
Research Program -

Los Angeles, CA  August 23, 2017  ImmunoCellular Therapeutics, Ltd. (ImmunoCellular) (NYSE MKT: IMUC) announced today that it
plans to continue strategies to refocus and reallocate its available resources on its promising
Stem-to-T-Cell
research program.
ImmunoCellulars
Stem-to-T-Cell
program is designed to provide a novel method of harnessing the immune system to manufacture
antigen-specific killer T cells that target and destroy cancer cells and provide long-term immuno-surveillance against tumor recurrence. The
Stem-to-T-Cell
platform has the potential to address many types of cancer, including both solid and hematological tumors.

Key anticipated near-term milestones in this program include: completion of loading of the T cell receptor DNA sequence into a viral vector during the third
quarter of 2017 and transfection of the human hematopoietic stem cells by the loaded viral vector during the fourth quarter of 2017. These transfected stem cells are anticipated to ultimately be able to produce an unlimited supply of killer T cells
bearing the desired T cell receptor. The killer T cells are designed to specifically target and destroy tumor cells. This phase of the
Stem-to-T-Cell
development is an important component of the
proof-of-concept
work for this technology. Once
proof-of-concept
has been established,
ImmunoCellular can progress to testing in preclinical models.

Immunotherapies are being widely investigated as a way to develop highly specific
anticancer therapies. The goal of most of these immunotherapies is to create a population of killer T cells that are programmed to destroy tumor cells. ImmunoCellulars
Stem-to-T-Cell
platform represents a novel and more direct approach to generating killer T cells by using the patients stem cells as starting material. Thus, ImmunoCellulars
Stem-to-T-Cell
technology shares some similarities with other immuno-oncology technologies, such as
CAR-T,
and could potentially be used in combination approaches. Unlike
CAR-T
therapies which deliver a large bolus of active T cells into the patients circulation
and have been associated with toxicity in some patients, ImmunoCellulars approach enables a more gradual and measured release of killer T cells and has the potential for lower toxicity while also yielding a more sustained response.

Anthony J. Gringeri, PhD, President and Chief Executive Officer, commented: The board and management of ImmunoCellular remain committed to pursuing a
viable strategic path forward for the Company, with the goal of realizing the value of our immuno-oncology technology platform and assets. Toward that end, we have successfully secured funding for the Company that extends our operating runway. We
are focusing resources on advancing our research-stage

Stem-to-T-Cell
program in collaboration with leading academic researchers
and contract laboratories. We are also continuing to explore opportunities to partner our development-stage programs.

Dr. Gringeri further
commented: Consistent with our commitment to reduce our costs and operate efficiently and cost-effectively, we have significantly streamlined our operations and organization. Mindful of the demands on our cash resources, and the reduced scope
of our operations, our board of directors has decided to reduce its membership, while still providing required representation and fulfilling its stewardship and fiduciary responsibilities. Two of our valued board members, Mark A. Schlossberg and
Gregg LaPointe, have therefore chosen to leave the board, effective August 15, 2017. We are deeply appreciative of their service and counsel, and their continued support for ImmunoCellulars mission and strategy. We wish them all the best
in their future endeavors.

The Company is in the process of making significant reductions in its operating costs. Besides the previously announced
suspension of the phase 3 registration trial of
ICT-107
the Company is in the process of reducing its operating expenses through personnel and facility reductions. The Company plans to improve its liquidity by
obtaining additional financing through the issuance of financial instruments such as equity and warrants or through the receipt of grants and awards. Additionally, the Company continues to evaluate its strategic alternatives, which may include a
potential merger, consolidation, reorganization or other business combination, as well as the sale of the Company or the Companys assets.

Business Update Conference Call and Webcast Today

ImmunoCellular plans to hold a conference call and webcast today at 5:00 pm ET to provide a business update. The call will be hosted by Anthony J. Gringeri,
PhD, President and Chief Executive Officer.

Interested parties who wish to listen to the webcast should visit the Investor Relations section of ImmunoCellulars website at
www.imuc.com
, under the Events and Presentations tab. A replay of the webcast
will be available one hour after the conclusion of the event.

The conference call will contain forward-looking statements. The information
provided on the teleconference is accurate only at the time of the conference call, and ImmunoCellular will take no responsibility for providing updated information except as required by law.

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular
Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellulars pipeline includes: a
Stem-to-T-Cell
research program, which engineers

hematopoietic stem cells to generate cytotoxic T cells;
ICT-121,
a patient-specific, dendritic cell-based immunotherapy targeting CD133 found in recurrent
glioblastoma; and
ICT-140,
a patient-specific, dendritic cell-based immunotherapy targeting ovarian cancer. ImmunoCellular recently announced the wind down of its phase 3 trial of
ICT-107
in
HLA-A2
patients while it pursues a collaborative arrangement or sale of its
ICT-107
program. To learn more about
ImmunoCellular, please visit
www.imuc.com
.

Forward-Looking Statements for ImmunoCellular Therapeutics

This press release contains certain forward-looking statements, including statements regarding ImmunoCellulars intentions and current expectations
concerning, among other things, ImmunoCellulars ability to advance its
Stem-to-T-Cell
program and achieve near-term
milestones; ImmunoCellulars ability to finance its ongoing operations, reduce costs and minimize or defer the costs of restructuring in order to enable its immunotherapy program; the potential benefits and therapeutic utility of
ImmunoCellulars
Stem-to-T-Cell
program and other product candidates; the likelihood, timing and outcome of
ImmunoCellulars possible strategic alternatives, including a partnership or restructuring;; and ImmunoCellulars ability to achieve its other clinical, operational, strategic and financial goals. Forward-looking statements are not
guarantees of future performance and are subject to a number of risks and uncertainties, including the availability of resources to continue to develop ImmunoCellulars product candidates and the uncertain timing of completion and success of
ImmunoCellulars
proof-of-concept
work and preclinical trials. Additional risks and uncertainties are described under the heading Risk Factors in
ImmunoCellulars most recently filed quarterly report on Form
10-Q
for the period ended June 30, 2017. Except as required by law, ImmunoCellular undertakes no obligation to update or revise any
forward-looking statements, whether as a result of new information, future events or otherwise.